| OHDSI Home | Forums | Wiki | Github |
A few of us were chatting at the OHDSI Symposium about running a network study to characterize the inpatient sedation medication pathway for agitated patients. Putting the discussion on the forums so other people can join in.
We’re going to set-up time to chat as a group. If you’d like to participate, please fill out the Doodle poll ASAP: https://doodle.com/poll/k339gpn2r73xrb35.
(cc: @mattspotnitz @nbareis @cukarthik @Dymshyts @mvanzandt @tom.white.md)
Is this based on or related to the recent systematic reviews that came out around antipsychotics and delirium?
In case anyone didn’t see those, both came out in Annals, concluded no effect in preventing delirium (https://annals.org/aim/fullarticle/2749494/antipsychotics-preventing-delirium-hospitalized-adults-systematic-review) or in treating delirium (https://annals.org/aim/fullarticle/2749495/antipsychotics-treating-delirium-hospitalized-adults-systematic-review)
Thank you for sharing the systematic reviews. However, this study intends to be a different kind of analysis.
I understand you’re trying to do a treatment pathway/characterization study. Just thought it would be helpful for the context in which you’re characterizing treatment. Could tell a much more powerful story if, for example, 90% of patients received antipsychotics as part of 1st-line therapy (which is generally what happens in practice, either that or Ativan, or both) and now we have recent evidence which says antipsychotics are not that helpful
Thanks @rchen for passing these articles along! Leaves a lot of food for thought. Looking forward to seeing what the data tells us!